CAR-T Cell Therapy Targeted Non-Hodgkin's Lymphoma: Clinical Development and Challenge

Abstract

Non-Hodgkin's lymphoma incidence has been rising worldwide in last few years. And the dismal prognosis following treatment to cure relapsed or resistant T-cell lymphoma and B-cell malignancies. Today, this therapy has already achieved incredible results with the field of non-Hodgkin's lymphoma. It becomes a new pillar in the treatment of cancer and shows great promise. Recently, there have been a number of new clinical studies and technology discoveries that have led to significant clinical responses to this therapy in certain subpopulations of Non-Hodgkin's Lymphoma. However, there are still many structural and functional challenges that limit the therapeutic efficacy of this therapy. Therefore, new strategies and ideas are needed to overcome the current challenges. The most recent developments and clinical trial findings on this therapy's effectiveness in treating NHL are covered in this review, as well as discussing the limitations of this therapy and the current solutions and strategies to address them.